Brief: Neurosense Reports Additional Positive Results From ALS Phase 2B Trial

Neurosense Therapeutics

21/02/2024 13:39

Feb 21 (Reuters) - Neurosense Therapeutics Ltd  NRSN.O :
    * NEUROSENSE REPORTS ADDITIONAL POSITIVE RESULTS FROM ITS
ALS
PHASE 2B PARADIGM TRIAL
    * NEUROSENSE THERAPEUTICS LTD - PRIMEC DEMONSTRATED A
CLINICALLY
MEANINGFUL EFFECT ON QUALITY OF LIFE AND ON COMPLICATION
FREE-SURVIVAL FOR PATIENTS WITH ALS
    * NEUROSENSE THERAPEUTICS LTD - FURTHER ANALYSIS OF PARADIGM
IS ON
TRACK WITH NEUROFILAMENT RESULTS EXPECTED IN Q1
    * NEUROSENSE THERAPEUTICS LTD - TDP-43 AND PROSTAGLANDINJ2
BIOMARKERS EXPECTED IN FIRST HALF OF 2024
    * NEUROSENSE THERAPEUTICS - STANDARD ALS MEASURE ALSFRS-R
ALREADY
SHOWED STATISTICALLY SIGNIFICANT EFFECT OF PRIMEC ON SLOWING
DOWN DISEASE PROGRESSION

Source text for Eikon:  ID:nPn7Qm1yka 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))